
Brian Robert Smith
MD Student, expected graduation Spring 2026
All Publications
-
On a scale from one to ten.
Palliative & supportive care
2022: 1
View details for DOI 10.1017/S1478951522000803
View details for PubMedID 35735029
-
Induction.
Anesthesiology
2022
View details for DOI 10.1097/ALN.0000000000004286
View details for PubMedID 35727085
-
Letter from a medical oncology scribe
Palliative & Supportive Care
2022
View details for DOI 10.1017/S1478951522000281
-
On Diction.
JAMA oncology
2021
View details for DOI 10.1001/jamaoncol.2021.2730
View details for PubMedID 34382997
-
High-Parametric Evaluation of Human Invariant Natural Killer T Cells to Delineate Heterogeneity in Allo- and Autoimmunity.
Blood
2020
Abstract
Human invariant natural killer T cells (iNKTs) are a rare innate-like lymphocyte population that recognize glycolipids presented on CD1d. Studies in mice have shown that these cells are heterogenous and capable of enacting diverse functions, and the composition of iNKT subsets can alter disease outcomes. In contrast, far less is known about how heterogeneity in human iNKTs relates to disease. To address this, we use a high-dimensional, data-driven approach to devise a framework to parse human iNKT heterogeneity. Our data revealed novel and previously described iNKT phenotypes with distinct functions. In particular, we found two phenotypes of interest: 1) a population with Th1 function that was increased with iNKT activation characterized by HLA-II+CD161- expression, and 2) a population with enhanced cytotoxic function characterized by CD4-CD94+ expression. These populations, respectively, correlate with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation and with new onset type 1 diabetes. Our study identifies human iNKT phenotypes associated with human disease that could aid in the development of biomarkers or therapeutics targeting iNKTs.
View details for DOI 10.1182/blood.2019001903
View details for PubMedID 31935280